NEJM - Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

NEJM - Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

The New England Journal of MedicinePatients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment...
BMJ - Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

BMJ - Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

British Medical JournalTo estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the UK variant of concern B.1.1.7), admissions to hospital,...
THE LANCET - Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

THE LANCET - Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

The LancetMany patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19.
JAMA - Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted

JAMA - Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted

JAMA NETWORK

The results do not support routine empirical use of intermediate-dose prophylactic anticoagulation in unselected patients with COVID-19 admitted to the ICU.

JAMA - Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19A Systematic Review and Meta-analysis

JAMA - Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19A Systematic Review and Meta-analysis

JAMA NETWORKIn a meta-analysis of 4 peer-reviewed and published randomized clinical trials including 1060 patients with COVID-19 treated with convalescent plasma vs control, the risk ratio for mortality was 0.93 and after the addition of 6...
NEJM - BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

NEJM - BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

The New England Journal of MedicineAs mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled...
BMJ - Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study

BMJ - Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study

British Medical JournalOf 4297 patients admitted to hospital with covid-19, 3627 (84.4%) received prophylactic anticoagulation within 24 hours of admission. More than 99% (n=3600) of treated patients received subcutaneous heparin or enoxaparin....
JAMA - Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children

JAMA - Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children

JAMA NETWORKMultisystem inflammatory syndrome in children (MIS-C) is the most severe pediatric disease associated with severe acute respiratory syndrome coronavirus 2 infection, potentially life-threatening, but the optimal therapeutic strategy...
BMJ - Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

BMJ - Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

British Medical JournalThe coronavirus disease 2019 (covid-19) pandemic has led to profound worldwide health, economic, and social losses. As of October 2020, more than 40 million people have received a diagnosis of covid-19 and one million...
NEJM - Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19

NEJM - Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19

The New England Journal of MedicineThe duration of transmissibility of coronavirus disease 2019 (Covid-19) and the associated level of contagion have been uncertain. We cultured severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in...
AMP - The Role of Pharmacovigilance in the COVID-19 Pandemic

AMP - The Role of Pharmacovigilance in the COVID-19 Pandemic

Acta Médica PortuguesaA farmacovigilância foi definida pela Organização Mundial da Saúde como a ciência e as atividades relacionadas com a deteção, avaliação, compreensão e prevenção de eventos adversos ou qualquer outro problema de segurança...
THE LANCET - 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

THE LANCET - 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

The LancetThe long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patients with COVID-19 who have been discharged from hospital and investigate the...
NEJM - Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

NEJM - Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

The New England Journal of MedicineTherapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because...
NEJM - Tocilizumab in Patients Hospitalized with Covid-19

NEJM - Tocilizumab in Patients Hospitalized with Covid-19

The New England Journal of MedicineThe efficacy of tocilizumab was tested in a randomized, controlled trial involving patients with Covid-19 who had fever, pulmonary infiltrates, or a need for supplemental oxygen. The treatment had no significant...
NEJM - Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

NEJM - Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

The New England Journal of MedicineWorld Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a — in patients hospitalized with...
12345
Eventos
«setembro de 2021»
segterquaquisexsábdom
303112345
6789101112
13141516171819
20212223242526
2728
Dia 28 de setembro às 17h00

Dia 28 de setembro às 17h00

A chill out session prevista para dia 24 de setembro ao fim da tarde foi adiada, tendo em conta a previsão meteorológica. Assim, passará a realizar-se no dia 28 de setembro, a partir das 17h00, no Jardim da Ordem dos Médicos, em Lisboa. A sessão inclui uma apresentação da médica e cantora Catarina Munhá, a partir das 18h00.

Ler mais
2930123
45678910
Categorias

Categorias

Arquivo de Notícias

Arquivo